Metrics as of 10/13/2026, 06:52 PM (Berlin time), refresh in progress.
Rallybio Stock
Rallybio Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Stephen Uden
- Employees
- 7
- Market cap
- $89 M
- IPO
- 29/07/2021
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical…
Rallybio stock: price history
1D
-0.4%
1W
-2.1%
1M
-0.9%
6M
+102.7%
YTD
+204.6%
1Y
+296.2%
2Y
+90.0%
5Y
-88.2%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~4% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Rallybio
Analyst assessment of Rallybio
0
STRONG BUY
4
BUY
5
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Hold
As of: 15/04/2025
Rallybio stock metrics
P/E
2.11
P/B
1.01
EV/EBITDA
-0.15
RETURN ON EQUITY
46.2%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
54.4%
FLOAT SHARES
2,887,676
AVG. DAILY VOLUME (30D)
9,354
Insider transactions (SEC)
Hopfner Robert Lorne
Hopfner Robert Lorne
Hopfner Robert Lorne
Lieber Jonathan I
Uden Stephen
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Rallybio stock
What does Rallybio do?
Rallybio Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Stephen Uden, the company employs around 7 people.
The IPO was on 29/07/2021; the stock trades on NASDAQ under the ticker RLYB.
What do analysts say about Rallybio stock?
9 analysts rate the stock, the consensus is Hold (as of 15/04/2025).
This is an external assessment, not a statement by Market Jury.
When does Rallybio report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -4% stronger than usual.
Does Rallybio pay a dividend?
No, Rallybio currently does not pay a dividend.
Which stocks are comparable to Rallybio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Rallybio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Rallybio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.